Sign inJoin waitlistJoin the waitlist

Beth Kirkpatrick

Department Chair, Microbiology and Molecular Genetics · University of Vermont, Larner College of Medicine

Credentials: · · · · · ·

History

Microbiology and Molecular Genetics Department · University of Vermont, Larner College of Medicine
2018–Present
Department of Biochemistry · University of Vermont, Larner College of Medicine
Present
University of Vermont, Larner College of Medicine
2020–Present

Infectious Disease
Robert Larner College of Medicine
1995–1997
Internal Medicine
University of Rochester Medicine
1992–1995
Albany Medical College
1988–1992
Bates College

Research

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years
JAMA Pediatrics · 2018 · 655 citations
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
New England Journal of Medicine · 2021 · 549 citations
Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh
EBioMedicine · 2015 · 229 citations

William Petri
50 papers
Kristen Pierce
28 papers · 6 as a fellow
Anna Durbin
24 papers
BL
Benjamin Lee
19 papers · 2 as a fellow
Caroline Lyon
10 papers · 1 as a resident
Eric Houpt
8 papers
James Platts-Mills
8 papers · 1 as a fellow
JD
Jeffrey Donowitz
7 papers · 3 as a fellow
Jessica Crothers
7 papers
Mary Walsh
7 papers
Christopher Huston
6 papers
DT
David Tribble
6 papers

Grants

Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine
National Institute of Allergy and Infectious Diseases · U01
PI · $5.1M · University of Vermont & St Agric College
2019–2029
Translational Global Infectious Diseases Research Center
National Institute of General Medical Sciences · P20
Contact PI · $22.6M · University of Vermont & St Agric College
2018–2028
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $6.3M · University of Vermont & St Agric College
2019–2027
A Phase I/II Trial of the Safety, Tolerability and Immunogenicity of a Live Attenuated Tetravalent Dengue Virus Vaccine in Adults in Dengue-Endemic Bangladesh
National Institute of Allergy and Infectious Diseases · R34
Contact PI · $234K · University of Vermont & St Agric College
2016–2017

Clinical trials

Dengue Controlled Human Infection Model in Dhaka, Bangladesh
Principal investigator · Active not recruiting · Phase 2
Beth Kirkpatrick
2021–2025
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
Principal investigator · Completed · Phase 1
University of Vermont
2019–2020
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2013–2015
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)
Principal investigator · Completed · Phase 1
International Vaccine Institute
2012–2016

Honors

FASTMH